The authors reply

New England Journal of Medicine

Volumn 369, Issue 17, 2013, Pages 1659-1660

  Parker, Chris ^a   Sartor, Oliver ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYETHYLIDINE DIPHOSPHONATE RHE 188; PLACEBO; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; UNCLASSIFIED DRUG;

BONE METASTASIS; DRUG EFFICACY; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84886298505     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1310231     Document Type: Letter

References (3)

1. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21:2869-75.
2. Biersack H-J, Palmedo H, Andris A, et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 2011;52:1721-6.
3. Sartor AO, Amariglio R, Wilhelm S, et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol 2013;31:Suppl:5080. abstract.